Summit Doubles Down On Lung Cancer With Ivonescimab Trial Expansion

The changes expand the commercial potential of the PD-1/VEGF targeting immunotherapy's trial, but worries about delays and endpoint success have reigned in Summit's formerly skyrocketing share price.